Introduction
There is increasing evidence demonstrating that modulation of the insulin/insulin growth factor (IGF) axis can alter aging phenotypes and longevity in animal models. Attempts to alter activation and regulation of this pathway for therapeutic benefit in patients with cancers are currently ongoing. While this is an extremely exciting area of research, the fact that the insulin/IGF pathway is responsible for regulating normal growth and development and does not act only at the local level raises concerns that altering insulin/IGF signaling may have unintended consequences on various diseases of aging. This underscores the importance of local modulation of events where a process may be beneficial in one organ or local microenvironment and detrimental in another.
The two most common diseases of aging are cardiovascular disease (CVD) and cancer. CVD is the leading cause of morbidity and mortality in the United States (Available from: http:// www.cdc.gov/nchs/deaths.htm). Cancer is the second leading cause of death in the United States with the majority of people dying from metastatic disease (Available from: http:// www.cdc.gov/nchs/deaths.htm).
Metastatic dissemination requires tumor cells to gain access to the lymphatic and blood vascular systems and subsequent migration into and growth in secondary sites. The insulin/IGF pathway is known to play an important role in the development and prognosis of CVD. It is also an important mediator of cancer development and metastasis with roughly 25% of human malignancies having abnormal activation of this pathway (Hanahan and Weinberg, 2000) .
Given this, a more complete understanding of the consequences of altering insulin/IGF signal transduction pathways is important to understanding not only the biology of aging as it relates to longevity but also to the development and progression of diseases like cancer and CVD. This review will focus on the role of the insulin/IGF axis in aging and how the changes in insulin/IGF concentrations and signaling that occur during aging may be permissive for development and spread of cancer, and the development and progression of CVD.
Insulin and type I insulin growth factor receptor pathway
The insulin receptor (IR) and the type I IGF-I receptor (IGF-IR) are highly conserved structures that evolved from a single ancestral receptor (Fig. 1) . Structurally, they consist of two half-receptors which each has an extracellular component and a transmembrane subunit that possesses tyrosine kinase activity (Adams et al., 2000; Pollak, 2008a) . The divergence of these receptors from one another is hypothesized to have resulted from more complex animals needing to independently regulate glucose uptake from cell survival and proliferation (Pollak, 2008a) .
In complex mammals, for example, insulin is primarily involved in regulating metabolic processes. It is secreted by the pancreas predominantly after food intake, binds to the IR and at physiological concentrations has low affinity for IGF-IR (Belfiore, Ageing Research Reviews 10 (2011) 62-70 
